Back to search

Article

Efficient control of IL-6, CRP and Ferritin in Covid-19 patients with two variants of Beta-1,3-1,6 glucans in combination, within 15 days in an open-label prospective randomized clinical trial

2021-12-16

Abstract excerpt

<h4>Background</h4> Several biomarkers, including C-reactive protein (CRP), ferritin, fibrinogen, D-dimer, and Interleukin-6 (IL-6), are established predictors of disease severity and respiratory failure in COVID-19 patients. <h4>Objective</h4> In this randomized clinical study, we evaluated the efficiency of the combination of two variants’ AFO-202 and N-163 strains of Aureobasidium Pullulans produced 1,3-1,6 bet...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
5f2ae37d-fb76-5a21-b084-a8004ca5e944
DOI
10.1101/2021.12.14.21267778
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 10 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Efficient control of IL-6, CRP and Ferritin in Covid-19 patients with two variants of Beta-1,3-1,6 glucans in combination, within 15 days in an open-label prospective randomized clinical trialDOI 10.1101/2021.12.14.21267778
Evolution of COVID-19 patients treated with ImmunoFormulation, a combination of nutraceuticals to reduce symptomatology and improve prognosis: a multi-centred, retrospective cohort studySemantic proximity
Seven COVID-19 Patients Treated with C-Reactive Protein (CRP) ApheresisSemantic proximity
Determination of both the expression and serum levels of epidermal growth factor (EGF) and transforming growth factor-β1 (TGFβ1) genes in SARS-CoV-2Semantic proximity
Convalescent plasma in the management of moderate COVID-19 in India: An open-label parallel-arm phase II multicentre randomized controlled trial (PLACID Trial)Semantic proximity
Clinical and Non-clinical Proof of Concept Supporting the Development of RJX As an Adjunct to Standard of Care Against Severe COVID-19Semantic proximity
COVID-19 convalescent plasma to treat hospitalised COVID-19 patients with or without underlying immunodeficiency: a randomized trialSemantic proximity
Dose-Dependent Interleukin-6 Responses Induced by Clinical Bacterial Isolates in an Ex Vivo Whole-Blood Model: A Laboratory-Based Experimental StudySemantic proximity
Dose-Dependent Interleukin-6 Responses to Clinical Bacterial Isolates in an Ex Vivo Whole-Blood Model: A Laboratory-Based Experimental StudySemantic proximity
Favipiravir and/or Nitazoxanide: a randomized, double-blind, 2x2 design, placebo-controlled trial of early therapy in COVID-19 (FANTAZE).Semantic proximity
Guduchi Ghanavati to Improve Immune Status and General Health in the Population at High Risk of COVID-19: Results of An Open-Label Non-Randomized Clinical Trial from IndiaSemantic proximity
Select a neighboring publication to make it the new centre.